GGDM 2016 Current "Real-Life"-Studies on the first Infliximab-Biosimilar (Remsima®) give Treatment Safety for CED

被引：0
|
作者：
不详
机构：
来源：
VISCERAL MEDICINE | 2016年 / 32卷 / 05期
关键词：
INNOVATOR INFLIXIMAB; PARALLEL-GROUP; DOUBLE-BLIND; EFFICACY; CT-P13;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：377 / 377
页数：1
相关论文
共 22 条
  • [1] Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab
    Vegh, Zsuzsanna
    Kurti, Zsuzsanna
    Lakatos, Peter L.
    DIGESTIVE DISEASES, 2017, 35 (1-2) : 101 - 106
  • [2] Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn's disease and ulcerative colitis
    Gheorghe, C.
    Svoboda, P.
    Dimitriu, A.
    Mateescu, B.
    Kotzev, I.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S316 - S317
  • [3] The Safety and Effectiveness of Infliximab Biosimilar in Managing Rheumatoid Arthritis: A Real-Life Experience from Jordan
    Alawneh, Khaldoon
    Al-Mistarehi, Abdel-Hameed
    Qandeel, Ali
    Jaber, Ruba
    Alomari, Safwan
    Kheirallah, Khalid A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2022, 2022
  • [4] Remsima®: Experiences from more than 16,000 Patient Years Real-life Data confirm Efficacy and Safety in CED
    不详
    VISCERAL MEDICINE, 2016, 32 (01) : 63 - 63
  • [5] Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis
    Codreanu, Catalin
    Sirova, Klara
    Jarosova, Katerina
    Batalov, Anastas
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (10) : 1763 - 1769
  • [6] EFFECTIVENESS AND SAFETY OF BIOSIMILAR INFLIXIMAB (CT-P13) IN A REAL-LIFE SETTING IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Codreanu, C.
    Sirova, K.
    Jarosova, K.
    Batalov, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 489 - 489
  • [7] Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis
    Gheorghe, Cristian
    Svoboda, Pavel
    Mateescu, Bogdan
    JOURNAL OF DRUG ASSESSMENT, 2019, 8 (01) : 129 - 134
  • [8] Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
    Benucci, Maurizio
    Li Gobbi, Francesca
    Bandinelli, Francesca
    Damiani, Arianna
    Infantino, Maria
    Grossi, Valentina
    Manfredi, Mariangela
    Parisi, Simone
    Fusaro, Enrico
    Batticciotto, Alberto
    Sarzi-Puttini, Piercarlo
    Atzeni, Fabiola
    Meacci, Francesca
    IMMUNOLOGIC RESEARCH, 2017, 65 (01) : 419 - 422
  • [9] Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
    Maurizio Benucci
    Francesca Li Gobbi
    Francesca Bandinelli
    Arianna Damiani
    Maria Infantino
    Valentina Grossi
    Mariangela Manfredi
    Simone Parisi
    Enrico Fusaro
    Alberto Batticciotto
    Piercarlo Sarzi-Puttini
    Fabiola Atzeni
    Francesca Meacci
    Immunologic Research, 2017, 65 : 419 - 422
  • [10] Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients
    Tursi, Antonio
    Mocci, Giammarco
    Lorenzetti, Roberto
    Allegretta, Leonardo
    Brandimarte, Giovanni
    Cassieri, Claudio
    Colucci, Raffaele
    De Medici, Antonio
    Faggiani, Roberto
    Ferronato, Antonio
    Fiorella, Serafina
    Forti, Giacomo
    Franceschi, Marilisa
    Gallina, Sara
    Giorgetti, GianMarco
    Grasso, Giuseppina
    Larussa, Tiziana
    Luzza, Francesco
    Penna, Antonio
    Pica, Roberta
    Piergallini, Simona
    Porciello, Sarah
    Pranzo, Giuseppe
    Rodino', Stefano
    Scorza, Stefano
    Sebkova, Ladislava
    Zampaletta, Costantino
    Elisei, Walter
    Picchio, Marcello
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (05) : 670 - 679
123